June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Clinical, Adaptive Optics Imaging and Electrophysiologic Outcomes in Autoimmune Retinopathy Patients with Rituximab
Author Affiliations & Notes
  • Samaneh Davoudi
    Ophthalmology, MEEI, Arlington, Massachusetts, United States
  • Damla Sevgi
    Ophthalmology, MEEI, Arlington, Massachusetts, United States
  • Cagla Yasa
    Ophthalmology, MEEI, Arlington, Massachusetts, United States
  • Nazanin Ebrahimiadib
    Ophthalmology, MEEI, Arlington, Massachusetts, United States
  • Inês Laíns
    Ophthalmology, MEEI, Arlington, Massachusetts, United States
  • Ramak Roohipoor
    Ophthalmology, MEEI, Arlington, Massachusetts, United States
  • Evangelia Papavasilieou
    Ophthalmology, MEEI, Arlington, Massachusetts, United States
  • Jason Comander
    Ophthalmology, MEEI, Arlington, Massachusetts, United States
  • Lucia Sobrin
    Ophthalmology, MEEI, Arlington, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Samaneh Davoudi, None; Damla Sevgi , None; Cagla Yasa, None; Nazanin Ebrahimiadib, None; Inês Laíns, None; Ramak Roohipoor, None; Evangelia Papavasilieou, None; Jason Comander, None; Lucia Sobrin, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1234. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Samaneh Davoudi, Damla Sevgi, Cagla Yasa, Nazanin Ebrahimiadib, Inês Laíns, Ramak Roohipoor, Evangelia Papavasilieou, Jason Comander, Lucia Sobrin; Clinical, Adaptive Optics Imaging and Electrophysiologic Outcomes in Autoimmune Retinopathy Patients with Rituximab
      . Invest. Ophthalmol. Vis. Sci. 2017;58(8):1234.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Given the proposed antibody-mediated of autoimmune retinopathy (AIR), rituximab as a therapeutic agent that targets B cells would seem reasonable. In this retrospective case series, we evaluate clinical and ancillary testing, including adaptive optics, outcomes in patients treated with rituximab.

Methods : 16 AIR patients (37.5 % male, mean age of 56 years) treated with rituximab were enrolled. The AIR diagnosis was based on clinical symptoms, electroretinogram (ERG) depression, presence of anti-retinal antibodies and exclusion of other diagnoses. All patients were treated initially with intravenous rituximab 375 mg/m2 weekly for 4 weeks or 1000 mg every other week for two doses. Treatment was repeated every 6 months or sooner if the patients were worsening. Visual acuity (VA), ERG and spectral domain optical coherence tomography (SD-OCT) results were recorded. OCT characteristics examined included total macular volume (TMV) and central subfield macular thickness (CSMT). A subset of patients was also imaged using Adaptive Optics Scanning Laser Ophthalmoscopy (AO-SLO). Cone densities were measured in ten 150 × 150 µm2 squares at each visit in the same locations at 1, 2 and 3 mm from the fovea. Outcomes before and six months after rituximab were compared with mixed model linear regression.

Results : Seven patients had paraneoplastic retinopathy and nine had non-paraneoplastic AIR. The mean follow-up period was 15 months (range 7-34 months) after rituximab initiation. 63% of eyes had stable VA during rituximab therapy. 14% of eyes experienced VA improvement. ERG parameters, CSMT and TMV did not decrease to a significantly degree over the rituximab treatment period. Six eyes had serial AO-SLO imaging. Cone densities did not change significantly over the treatment period.

Conclusions : VA was stable or improved in a majority of AIR patients while being treated with rituximab. OCT and ERG parameters, as well as AO-SLO cone densities, were stable during treatment. Studies with additional patients and longer follow up periods are needed to further explore the utility of rituximab in the management of AIR.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×